New obesity drug ARO-INHBE enters human trials
NCT ID NCT06700538
First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 30 times
Summary
This early-stage study tests a new drug called ARO-INHBE in 180 adults with obesity, some of whom also have type 2 diabetes. The main goal is to check safety and how the drug moves through the body. Researchers will also see if it helps with weight loss, either alone or with another weight-loss drug.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Research Site 1
RECRUITINGGrafton, Auckland, 1010, New Zealand
-
Research Site 2
RECRUITINGChristchurch, 8011, New Zealand
-
Research Site 3
RECRUITINGAuckland, 2025, New Zealand
Conditions
Explore the condition pages connected to this study.